相关实验视频
Updated: May 12, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
尼尔马特里尔维尔/里托纳维尔在严重或危急的COVID-19患者中降低了死亡率:一个多中心的回顾性队列研究
Heng Zhao1,2, Wanting Meng1, Xing Lv1
1Department of Pulmonary and Critical Care Medicine, Xijing Hospital of Air Force Medical University, Xi'an, China.
涅玛特里尔维尔/里托纳维尔显著降低了重症或危急COVID-19住院患者的死亡率. 这种抗病毒治疗与较低的28天和住院死亡率有关.
科学领域:
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
背景情况:
- 严重或危急的COVID-19具有很高的死亡风险.
- 尼尔马特里尔维尔/里托纳维尔在不严重的COVID-19中有效性已确立,但其对严重/危急住院病例的影响尚不清楚.
研究的目的:
- 评估尼尔马特里尔维尔/里托纳维尔在重症或危急COVID-19住院患者中的有效性.
- 评估nirmatrelvir/ritonavir对这种患者群的死亡率和住院时间的影响.
主要方法:
- 一项多中心回顾性队列研究包括386名住院患有严重或危急COVID-19的成年人.
- 患者被分为尼尔马特雷尔维尔/里托纳维尔和非抗病毒组.
- 主要结局是28天死亡率;次要结局包括住院死亡率和住院时间.
主要成果:
- 尼马特里尔维尔/里托纳维尔的使用与28天死亡率显著降低 (6.9%与15.5%) 和住院死亡率 (8.1%与16.0%) 相关.
- 经过调整后的分析证实,尼马特里尔维尔/里托纳维尔独立降低了28天和住院死亡的风险.
- 在特定的子组中显著降低死亡风险,包括老年人和重症患者.
结论:
- 尼尔马特里尔维尔/里托纳维尔在住院的严重或危急的COVID-19患者中显示出显著的死亡率降低.
- 这些发现支持对这种高风险人群的尼马特里尔维尔/里托纳维尔的临床使用.
更多相关视频
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
相关概念视频
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Bioavailability Study Design: Healthy Subjects Versus Patients
Antimicrobial Effectiveness
Cytomegalovirus Disease